NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

BillionToOne BLLN

BillionToOne listed on Nasdaq on 6 Nov 2025 and is not in the S&P 500. It is worth $4.3 billion. Its price history starts on 7 Nov 2025. Its board has 7 directors, 5 of them independent. 6 other officers are on file. At 30 Jun 2026, Adams Street Partners was its largest institutional holder, with 3.7% of the company.

Chair and CEO
Oguzhan Atay
Listed
6 Nov 2025 on Nasdaq
Headquarters
Menlo Park, CA
Market cap
$4.3B
19 Nov 2026 close
Revenue
$305M
Fiscal year 2025
Price to sales
14.1
Market cap over revenue

Financials

Financial history

Twelve months to 30 Sep 2026, from BillionToOne's quarterly filings.

Quarters since Sep 2024

Revenue
$437M
Up 72% on the year before
Net income
$49M
11.3% of revenue
Free cash flow
$34M
Operating cash flow less capital spending
P/E
87.2
Market cap over net income

Quarterly results

Each quarter's revenue, net income and free cash flow.

Sep 2024 to Sep 2026

$0$50M$100M$150M202420252026$123M

Revenue breakdown

BillionToOne's $123M of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.

Quarter to Sep 2026

  • Prenatal$104M, 84.8%
  • Oncology$17M, 13.9%
  • Clinical trial support and other services$2M, 1.3%

BillionToOne's market cap since November 2025

Weekly, up to 13 Nov 2026

Jan 2026MarMayJulSepNov$5.0B

Board and leadership

Board and officers

Board from the proxy filed 21 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (7)
Oguzhan AtayChair and CEONot independent · since 2016Chair and CEO2016No37
Thomas S. BremnerDirectorIndependent · since 2022 · Audit, CompensationPartner, Growth Equity team, Adams Street Partners, LLCDirector2022YesAudit, Compensation44
Firat IleriLead Independent DirectorIndependent · since 2019 · CompensationManaging Partner, Hummingbird VenturesLead Independent Director2019YesCompensation38
Krishna Kittu KolluriDirectorIndependent · since 2019 · Compensation (chair)Founding Partner, Neotribe VenturesDirector2019YesCompensation (chair)62
Anthony PaganoDirectorIndependent · since 2026 · Audit (chair)Chief Financial Officer and Executive Vice President, GenmabDirector2026YesAudit (chair)48
Akshay RaiDirectorIndependent · since 2024 · AuditU.S. Healthcare Investments Lead, Premji InvestDirector2024YesAudit42
David TsaoChief Technology OfficerNot independent · since 2016Chief Technology Officer2016No36
Officers (6)
Ross TaylorChief Financial OfficerLast filed 12 Nov 2025Chief Financial Officer
John Roderick ten BoschSVP of Laboratory OperationsLast filed 28 Sep 2026SVP of Laboratory Operations
Nancy JoAnn JohnsonSenior Vice President of Sales and Commercial OperationsLast filed 20 Jul 2026Senior Vice President of Sales and Commercial Operations
John ListerChief Administrative OfficerLast filed 12 Nov 2025Chief Administrative Officer
Thomas P. LynchGeneral Counsel, Chief Compliance Officer and SecretaryLast filed 21 Sep 2026General Counsel, Chief Compliance Officer and Secretary
Shan Riku SakakibaraChief Product OfficerLast filed 14 Sep 2026Chief Product Officer

Owners and trading

Largest institutional holders

Each fund group's share of BillionToOne. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 13.6% of BillionToOne.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $58.5 million of stock in 40 sales and made no open-market purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
2 Nov 2026SaleOguzhan AtayChairman and CEOChairman and CEOSale30,335$3.3M
2 Nov 2026SaleDavid TsaoChief Technology OfficerChief Technology OfficerSale20,000$2.2M
2 Nov 2026SaleJohn Roderick ten BoschSVP of Laboratory OperationsSVP of Laboratory OperationsSale2,834$321K
28 Oct 2026SaleOguzhan AtayChairman and CEOChairman and CEOSale11,000$1.3M
15 Oct 2026SaleOguzhan AtayChairman and CEOChairman and CEOSale5,150$516K
14 Oct 2026SaleOguzhan AtayChairman and CEOChairman and CEOSale5,850$574K
12 Oct 2026SaleOguzhan AtayChairman and CEOChairman and CEOSale19,334$1.8M
5 Oct 2026SaleDavid TsaoChief Technology OfficerChief Technology OfficerSale20,000$2.2M
5 Oct 2026SaleJohn Roderick ten BoschSVP of Laboratory OperationsSVP of Laboratory OperationsSale2,834$298K
28 Sep 2026SaleOguzhan AtayChairman and CEOChairman and CEOSale10,999$1.3M

Showing 10 of 40 trades

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

0 departures and 1 appointment of directors and officers and 21 large insider sales in the last two years.

Left the company or board 0Appointed 1WARN layoff notices 0Large insider sales 21Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of BillionToOne's insider sales.

Events, newest first

Showing 8 of 22 events

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.